ProMetic Provides its Proven Bio-Separation Technology to Achieve High Yield, Low Cost and High Purity Protein
MONTREAL, Quebec, June 22, 2001 – At the International Recovery of Biological Products Conference held recently in Cancun (Mexico), Genzyme Transgenics (GTC), in collaboration with ProMetic Life Sciences (ProMetic), presented data related to ton-scale manufacture of transgenic human serum albumin (tghSA). Ton-scale recovery and purification is a daunting challenge due to the magnitude and scale of the process, and the increased need for high purity. By combining their technologies, GTC and ProMetic were able to develop the technology that would make this ton-scale process cost-effective while achieving the volume and purity required for this pharmaceutical product.
Under this partnership, ProMetic has provided its purification technology, in particular its albumin binding absorbents (ligands), to be incorporated into GTC’s manufacturing process for tghSA produced from transgenic cows. The current world market consumes approximately 450,000 kg of albumin annually representing over $US 1.5 billion in sales.
Albumin is an abundant protein found in plasma. It helps retain water in the system. It is frequently used for patients who are hypovolemic and have lost large amounts of blood or fluids. Through this collaboration, GTC and ProMetic hope to furnish the growing need for this pharmaceutical protein.
“This collaboration underscores GTC’s confidence in our purification technology and speaks to the effectiveness and consistency for producing large-scale levels of biopharmaceuticals,” said Mr. Pierre Laurin, Chairman and CEO of ProMetic. “We are especially proud that we were able to meet the low manufacturing cost and high purity requirements essential for the feasibility of ton-scale production. This collaboration takes our long standing relationship with GTC one step further, together achieving a major technological feat that could set new precedents,” he added.
The collaboration between Genzyme and ProMetic was established in May 1999.
ProMetic Life Sciences Inc. (TSE: PLI), with headquarters in Montreal, Quebec, and additional facilities in the UK, owns proprietary enabling technology essential for use in therapeutics, large-scale drug purification, chemical genomics and proteomics, drug delivery and drug development. This existing technology can dramatically lower costs, increase yield, and improve efficacy of existing and new bio-pharmaceutical products. ProMetic accomplishes this through strategic partnerships and in-house therapeutic development. Additional information is available on the company’s website: prometic.com.
This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to the Company’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products and to obtain contracts for its products and services and commercial acceptance of advanced affinity separation technology. Shareholders are cautioned that these statements are predictions and these actual events or results may differ materially from those anticipated in these forward-looking statements.
Contacts: ProMetic Worldwide